US2014072621A1PendingUtilityA1

Composition and method to improve intestinal health

34
Assignee: DE LA MOTTE CAROLPriority: May 9, 2011Filed: May 8, 2012Published: Mar 13, 2014
Est. expiryMay 9, 2031(~4.8 yrs left)· nominal 20-yr term from priority
Inventors:Carol De La MotteSean Kessler
A61K 38/40A61K 47/644A61K 31/728A23L 33/19A23L 33/10A61K 47/61A61K 9/127
34
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Compositions and methods are provided for treating patients suffering from compromised intestinal function, including inflammatory bowel disease. The method comprises orally administering a composition comprising hyaluronan, where said hyaluronan has a molecular weight within the range of about 35 kDa.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A composition comprising
 hyaluronan fragments having a molecular weight of about 35 kDa; and   a pharmaceutically acceptable carrier suitable for oral administration, with the proviso that said composition is substantially free of hyaluronan fragments having a molecular weight of less than 10 kDa.   
     
     
         2 . The composition of  claim 1  wherein the composition comprises hyaluronan fragments having a molecular weight within the range of about 15 kDa to about 75 kDa. 
     
     
         3 . The composition of  claim 2  wherein the composition comprises hyaluronan fragments having a molecular weight of about 25 to about 50 kDa. 
     
     
         4 . The composition of  claim 1  wherein the composition is substantially free of hyaluronan fragments having a molecular weight of about 4.7 kDa. 
     
     
         5 . The composition of  claim 1  further comprising lactoferrin. 
     
     
         6 . The composition of  claim 5  wherein the lactoferrin and hyaluronan are present in a 1:1 molar ratio. 
     
     
         7 . The composition of  claim 5  wherein the lactoferrin is conjugated to hyaluronan. 
     
     
         8 . The composition of  claim 7 , wherein the composition further comprises liposomes wherein said lactoferrin and hyaluronan are linked to said liposomes. 
     
     
         9 . The composition of  claim 7  wherein said composition further comprises a probiotic. 
     
     
         10 . The composition of  claim 7  wherein said composition further comprises a standard infant formula. 
     
     
         11 . A method of treating patients in need of improved intestinal function, said method comprising the steps of
 identifying patients suffering from compromised intestinal function; and   orally administering a composition of  claim 3 .   
     
     
         12 . The method of  claim 11  where in the patient is suffering from an inflammatory bowel disease. 
     
     
         13 . The method of  claim 11  where in the patient is suffering from Crohn's disease. 
     
     
         14 . The method of  claim 11  wherein the composition further comprises lactoferrin. 
     
     
         15 . A pharmaceutical composition for oral administration, said composition comprising
 hyaluronan, having a molecular weight within the range of about 10 to about 50 KDa;   lactoferrin; and   a pharmaceutically acceptable carrier suitable for oral administration.   
     
     
         16 . A method of stimulating interferon mediated pathways, said method comprising the steps of
 orally administering to said patient a pharmaceutical composition comprising a purified hyaluronan, wherein the hyaluronan has a molecular weight within the range of about 10 to about 50 kDa.   
     
     
         17 . The method of  claim 16  wherein the composition further comprises lactoferrin.

Join the waitlist — get patent alerts

Track US2014072621A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.